[A22-87] Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V
Last updated 15.11.2022
Project no.:
A22-87
Commission:
Commission awarded on 17.08.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with advanced non-small cell lung cancer with METex14 skipping alterations
Result of dossier assessment:
- Patients after first-line therapy with a PD-1/PD-L1 antibody as monotherapy: added benefit not proven
- Patients after first-line therapy with platinum-containing chemotherapy: added benefit not proven
- Patients after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.